{"id":"adjuvanted-trivalent-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Injection site pain or erythema"},{"rate":"10-20","effect":"Myalgia"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Fatigue"},{"rate":"5-10","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated antigens from three influenza virus strains (typically two A subtypes and one B lineage) combined with an adjuvant that enhances the immune response. The adjuvant amplifies both humoral (antibody) and cell-mediated immunity, improving vaccine efficacy and duration of protection compared to non-adjuvanted formulations. This approach is particularly beneficial in populations with weaker immune responses, such as elderly individuals.","oneSentence":"An adjuvanted trivalent influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of influenza virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:19:29.815Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults"}]},"trialDetails":[{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT02529904","phase":"PHASE2","title":"ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Influenza","enrollment":120},{"nctId":"NCT00566345","phase":"PHASE3","title":"Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2007-11","conditions":"Influenza","enrollment":3670},{"nctId":"NCT01344057","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Seasonal Influenza","enrollment":63},{"nctId":"NCT03669627","phase":"PHASE2","title":"CT18 Infant Influenza Priming Study in Vaccine Naive Infants","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-11-01","conditions":"Influenza","enrollment":159},{"nctId":"NCT01964989","phase":"PHASE3","title":"Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-11","conditions":"Influenza Virus","enrollment":10644},{"nctId":"NCT02882100","phase":"PHASE4","title":"Adjuvanted Influenza Vaccination in U.S. Nursing Homes","status":"COMPLETED","sponsor":"Insight Therapeutics, LLC","startDate":"2016-04","conditions":"Influenza, Influenza-like Illness","enrollment":823},{"nctId":"NCT02523287","phase":"PHASE4","title":"Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2014-10-02","conditions":"Safety Markers of Adjuvanted Influenza Vaccine","enrollment":240},{"nctId":"NCT00841763","phase":"PHASE3","title":"Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Pandemic Influenza Disease","enrollment":3647},{"nctId":"NCT02933723","phase":"NA","title":"Immunogenicity of Influenza Vaccine in Long Term Care","status":"UNKNOWN","sponsor":"Insight Therapeutics, LLC","startDate":"2016-10","conditions":"Influenza","enrollment":200},{"nctId":"NCT03448705","phase":"PHASE1","title":"Safety of 4Fluart ID Suspension for Injection in Adult Subjects","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2018-01-31","conditions":"Human Influenza","enrollment":36},{"nctId":"NCT03699839","phase":"PHASE2, PHASE3","title":"Reducing the Burden of Influenza After Solid-Organ Transplantation","status":"COMPLETED","sponsor":"Oriol Manuel","startDate":"2018-10-26","conditions":"Influenza, Organ Transplantation","enrollment":619},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT03314662","phase":"PHASE3","title":"Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-10-17","conditions":"Influenza, Human","enrollment":1778},{"nctId":"NCT02831751","phase":"PHASE2","title":"Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2016-04","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":1001},{"nctId":"NCT03467074","phase":"","title":"Role of Interferon-λ and Vaccine Response","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-09-01","conditions":"Vaccine Response Impaired, Allogeneic Stem Cell Transplantation","enrollment":200},{"nctId":"NCT01222403","phase":"PHASE4","title":"A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-10","conditions":"Influenza","enrollment":767},{"nctId":"NCT01730378","phase":"PHASE4","title":"Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-05","conditions":"Influenza","enrollment":131},{"nctId":"NCT01811823","phase":"PHASE4","title":"Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2014-03-31","conditions":"Influenza, HIV, Tuberculosis","enrollment":301},{"nctId":"NCT01239537","phase":"","title":"Swine Flu (Influenza A H1N1) Follow on Vaccine Study","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-11","conditions":"Influenza","enrollment":560},{"nctId":"NCT01682369","phase":"PHASE2","title":"ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-09","conditions":"Influenza","enrollment":90},{"nctId":"NCT02362919","phase":"","title":"Influenza Vaccination Among the Elderly Individuals","status":"COMPLETED","sponsor":"Helmholtz Centre for Infection Research","startDate":"2015-02","conditions":"Influenza","enrollment":200},{"nctId":"NCT02560909","phase":"PHASE4","title":"Adjuvanted Influenza Vaccine in Stem Cell Transplant","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2015-10","conditions":"Transplantation, Influenza Vaccines","enrollment":73},{"nctId":"NCT02255279","phase":"PHASE3","title":"Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2014-10","conditions":"Influenza","enrollment":287},{"nctId":"NCT00644540","phase":"PHASE2","title":"Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-11","conditions":"FLU","enrollment":89},{"nctId":"NCT00408395","phase":"PHASE2","title":"Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-11","conditions":"Influenza","enrollment":281},{"nctId":"NCT00522067","phase":"PHASE2","title":"Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-06","conditions":"Influenza Disease","enrollment":52},{"nctId":"NCT01210898","phase":"PHASE3","title":"Immunogenicity and Safety of V70P5 Revaccination Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"Influenza","enrollment":197},{"nctId":"NCT02126761","phase":"PHASE1","title":"Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-06","conditions":"Influenza","enrollment":196},{"nctId":"NCT02686398","phase":"PHASE4","title":"Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2013-10","conditions":"Influenza, End Stage Renal Failure, Chronic Kidney Disease","enrollment":174},{"nctId":"NCT01152814","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-06","conditions":"Seasonal Influenza","enrollment":64},{"nctId":"NCT00644059","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Influenza, Human","enrollment":4902},{"nctId":"NCT02522754","phase":"PHASE1, PHASE2","title":"Development of an Intranasal Proteosome Influenza Vaccine","status":"COMPLETED","sponsor":"Hvivo","startDate":"2002-01","conditions":"Influenza","enrollment":174},{"nctId":"NCT01368796","phase":"PHASE4","title":"Comparison of 4 Influenza Vaccines in Seniors","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-07","conditions":"Influenza Vaccine","enrollment":953},{"nctId":"NCT01346592","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-04","conditions":"Influenza Disease","enrollment":6104},{"nctId":"NCT02225327","phase":"PHASE4","title":"MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2013-10","conditions":"Influenza, Human, Pneumococcal Infections","enrollment":224},{"nctId":"NCT01162122","phase":"PHASE3","title":"Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-08","conditions":"Influenza","enrollment":7109},{"nctId":"NCT01651104","phase":"PHASE2","title":"Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-07","conditions":"Human Influenza","enrollment":63},{"nctId":"NCT01879540","phase":"PHASE2","title":"Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-07","conditions":"Human Influenza","enrollment":63},{"nctId":"NCT00848887","phase":"PHASE1","title":"A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Influenza","enrollment":410},{"nctId":"NCT01508884","phase":"NA","title":"Intradermal Trivalent Influenza Vaccine With Imiquimod","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2012-01","conditions":"Chronic Illness","enrollment":93},{"nctId":"NCT01819155","phase":"PHASE2","title":"Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa","status":"COMPLETED","sponsor":"PATH","startDate":"2013-04","conditions":"Influenza","enrollment":296},{"nctId":"NCT01032395","phase":"PHASE3","title":"Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus","status":"COMPLETED","sponsor":"Chiltern Pesquisa Clinica Ltda","startDate":"2010-03","conditions":"H1N1 Influenza Virus, Chronic Pulmonary Disease, Chronic Heart Disease","enrollment":342},{"nctId":"NCT01032408","phase":"PHASE3","title":"Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection","status":"COMPLETED","sponsor":"Chiltern Pesquisa Clinica Ltda","startDate":"2010-04","conditions":"H1N1 Influenza Virus, Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":154},{"nctId":"NCT01424371","phase":"","title":"Adjuvanted Influenza Vaccine Effectiveness in the Elderly (65+Yrs)","status":"UNKNOWN","sponsor":"Fraser Health","startDate":"2011-11","conditions":"Influenza","enrollment":1000},{"nctId":"NCT01623232","phase":"PHASE1, PHASE2","title":"MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly","status":"WITHDRAWN","sponsor":"US Department of Veterans Affairs","startDate":"2012-10","conditions":"Influenza Vaccines, Aged","enrollment":""},{"nctId":"NCT01031719","phase":"PHASE3","title":"Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors","status":"COMPLETED","sponsor":"Chiltern Pesquisa Clinica Ltda","startDate":"2010-08","conditions":"H1N1 Influenza Virus, Invasive Solid Tumors","enrollment":59},{"nctId":"NCT01146119","phase":"PHASE2","title":"Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2010-07","conditions":"Influenza","enrollment":200},{"nctId":"NCT01459276","phase":"NA","title":"A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2011-10","conditions":"Influenza","enrollment":1206},{"nctId":"NCT01119157","phase":"PHASE4","title":"Comparison of the Cellular and the Humoral Immunogenicity, Safety of Different Trivalent Influenza Vaccines","status":"UNKNOWN","sponsor":"National Centre for Epidemiology, Hungary","startDate":"2008-11","conditions":"Healthy Volunteers","enrollment":85},{"nctId":"NCT00662272","phase":"PHASE1","title":"Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant","status":"COMPLETED","sponsor":"Colby Pharmaceutical Company","startDate":"2008-06","conditions":"Influenza","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":53,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fluad","aTIV"],"phase":"marketed","status":"active","brandName":"adjuvanted trivalent influenza vaccine","genericName":"adjuvanted trivalent influenza vaccine","companyName":"Insight Therapeutics, LLC","companyId":"insight-therapeutics-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"An adjuvanted trivalent influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of influenza virus. Used for Seasonal influenza prevention in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}